Here are four things to know.
1. Osmolex contains both immediate-release and extended-release forms of the drug amantadine, a known treatment for Parkinson’s. Patients take the pill once-daily in the morning.
2. The FDA also approved Osmolex to treat patients with drug-induced movement disorders.
3. The drug’s formulation is protected by three patents valid through March 2030.
4. Osmotica Pharmaceutical said it is finalizing commercialization plans to launch the drug as soon as possible, though the drugmaker did not share an exact date.
More articles on supply chain:
Novartis looks to auction off US generics business: 4 takeaway
AstraZeneca’s immunotherapy drug OK’d for lung cancer: 5 things to know
J&J reportedly seeks buyers for its $2B sterilization division: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.